Apyx Medical shares surge 14.2% after-hours following BTIG's Buy upgrade and $6 price target on Ayon launch momentum and U.S. expansion.

Apyx Medical surged 14.20% in after-hours trading following a BTIG upgrade to Buy from Neutral with a $6 price target. The upgrade cited positive early momentum from the Ayon launch, rising demand for skin tightening among GLP-1 users, and expansion opportunities outside the U.S. BTIG also highlighted improved visibility into sustainable profitability due to accelerating growth and cost controls. Craig-Hallum further raised its price target to $6 from $5, reinforcing the positive sentiment. The stock’s sharp rise aligns with the analyst upgrades and optimism around the company’s product pipeline and market potential.